Focused On-demand Library for B-cell lymphoma/leukemia 10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for protein-protein interfaces.

Fig. 1. The sreening workflow of Receptor.AI

This process entails comprehensive molecular simulations of the target protein, individually and in complex with essential partner proteins, along with ensemble virtual screening that focuses on conformational mobility in both its free and complex states. Potential binding pockets are considered at the protein-protein interaction interface and in remote allosteric locations to address every conceivable mechanism of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O95999

UPID:

BCL10_HUMAN

Alternative names:

B-cell CLL/lymphoma 10; CARD-containing molecule enhancing NF-kappa-B; CARD-like apoptotic protein; CED-3/ICH-1 prodomain homologous E10-like regulator; Cellular homolog of vCARMEN; Cellular-E10; Mammalian CARD-containing adapter molecule E10

Alternative UPACC:

O95999; Q5VUF1

Background:

B-cell lymphoma/leukemia 10 (BCL10) is pivotal in immune signaling, bridging CARD domain-containing proteins to immune activation. It plays a crucial role in both adaptive and innate immunity, activating NF-kappa-B and MAP kinase pathways, stimulating pro-inflammatory cytokine and chemokine expression. BCL10's involvement in forming the CBM complex upon activation by CARD domain-containing proteins underscores its significance in immune response regulation.

Therapeutic significance:

BCL10's association with Immunodeficiency 37 and mucosa-associated lymphoid type lymphoma highlights its therapeutic potential. Understanding BCL10's role could pave the way for innovative treatments targeting immune signaling pathways, offering hope for patients with these conditions.